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Background. Adjuvant chemotherapy for high-risk early-stage breast cancer patients significantly improves long-
term treatment results. The decision to administer chemotherapy is made based primarily on prognostic factors 
(defined by the pathological characteristics of the primary tumour and regional lymph nodes) and also on patient-
related factors, such as age, menopausal status and comorbidities. The guidelines on adjuvant chemotherapy have 
been established and reviewed for many years by several medical societies (NCCN, ESMO, PTOK, PUO) and experts 
of St. Gallen International Breast Cancer Conference. The aim of this study was to assess the pattern of adjuvant 
chemotherapy administration that had been routinely prescribed in four cancer centres in various regions of Poland 
(Opole, Kraków, Białystok, Poznań). 
Methods. 218 early-stage breast cancer patients treated in selected cancer centres during 3 consecutive months of 
2014 have been included in the analysis. The medical charts of the patients have been carefully evaluated. Data on 
the adjuvant chemotherapy administration have been reviewed retrospectively.
Results. The percentage of IHC tests in the analysed group was satisfactory. As much as 8 different chemotherapy 
regimens have been recorded. 98% of patients received anthracycline-based chemotherapy. Almost half of the pa-
tients (48.6%; 106/218) received taxanes. However, up to 27% (30/111) of patients with involved lymph nodes (pN+) 
did not received taxanes in the adjuvant setting. Trastuzumab was most frequently administered sequentially, which 
may be considered suboptimal.
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Introduction 
Since the 1990s there has been an observable decrease 
in breast cancer mortality rates in the countries of Western 
Europe and North America. This has been made possible 
thanks to improvements in early diagnosis, improvements in 
the efficiency of regional treatment as well as improvements 
in the efficacy of systemic treatment, including adjuvant 
chemotherapy.
The history of surgical treatment of breast cancer is 
more than 100 years long, yet it has also been known for 
a very long time that disease recurrence occurs even in cases 
of very extensive surgeries. The introduction and develop-
ment of chemotherapy in the 1950s and 1960s resulted in 
the development of the concept of systemic treatment as 
a follow-up therapy after the surgery.
The history of clinical studies concerning adjuvant 
chemotherapy completing surgical intervention goes back 
to 1950. The first attempts with the use of thioTEPA and 
5-fluorouracil consisted in perioperative chemotherapy that 
lasted for a few days [1]. The cancer cells which enter the 
circulatory system were then treated as the main source of 
the cancer’s spread. It was shown in 1968 that in premeno-
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pausal patients, the application of this method allows for 
a significantly longer survival period [2]. A decisive influ-
ence on the current face of chemotherapy was obtained 
thanks to the results of two studies from the beginning of 
the 1970s. In the first of them, carried out by the American 
group, NSABP (National Surgical Adjuvant Breast and Bowel 
Project) among women with metastases to axillary lymph 
nodes (N+ status), the effectiveness of a 2-year adjuvant 
treatment with melphalan was evaluated (the cycles were 
repeated every 6 weeks for 2 years or until the progression) 
in comparison with surgery alone [3]. The study showed 
a statistically significant prolongation of the time to recur-
rence of the disease with the application of chemotherapy 
and this effect was most clearly seen in women below 50 
years of age. In this group also the prolongation of the 
overall survival period was observed, yet the difference was 
not significant. Benefits related to chemotherapy was also 
observed in post-menopausal patients, yet the differences 
were not statistically significant. At the same time, in Italy, 
Bonadonna et al proved that post-operative chemotherapy 
with the CMF regimen allows prolongation of the time be-
fore the disease’s progression, in particular in the group 
of patients with metastases to more than three axillary 
lymph nodes. After three years of the follow-up period, the 
share of deaths caused by the cancer in the chemotherapy 
group was 10.4%, whilst in the control group this share was 
21.4% [4, 5]. The CMF regimen soon become a standard in 
the treatment of women with N+ status, in particular in the 
group of pre-menopausal patients. The data from this study 
were monitored in the next years which allowed confirma-
tion that the benefits of such treatments persist during 
the longer follow-up period [6]. In the years following the 
adjuvant treatment of patients with early breast cancer, 
anthracyclines and taxoids were introduced. 
From the 1970s onwards, dynamic progress in the clini-
cal studies concerning the treatment of early breast can-
cer resulted in a large inflow of data. In order to systema-
tise knowledge in this area, in 1983, at Oxford University, 
a group dealing with this issue was set up (Early Breast 
Cancer Trialists’ Collaborative Group, EBCTCG). Initially the 
group comprised several dozen specialists, but today this 
group consists of a few hundred investigators worldwide. 
The group, since its creation, has been gathering data from 
clinical studies concerning early breast cancer and regularly 
publishing the results, every 5 years, since 1985. These data 
offer a general perspective of varied treatment approaches 
in non-advanced breast cancer. The recent analysis comes 
from 2010 and was published in 2011. It comprised the 
histories of 101 patients with non-advanced breast cancer 
participating in clinical studies in 1973–2003 [7]. In patients 
with early breast cancer, the improvement in results was the 
effect of the application of adjuvant chemotherapy as op-
posed to the lack of such treatment; moreover the improve-
ment could be attributed to the addition of taxoids to the 
regimens based on anthracyclines and the standard use of 
larger anthracycline doses in comparison with CMF (Tab. I).
Some detailed recommendations are being created and 
updated on the basis of the current results of the studies. 
In the United States, the recommendations of the NCCN 
are binding, whilst in Europe — it is the consensus of the 
St. Gallen conference, organised every two years. American 
and European recommendations are not always compliant 
with each other, which is also the case with other cancers. 
Polish recommendations are made according to the St. Gallen 
consensus. Currently systemic treatment concerns the ma-
jority of breast cancer patients. 
The decision to introduce systemic adjuvant treatment 
should be based on the evaluation of individual risk of recur-
rence (prognostic and predictive factors) and the probability 
of benefit from the application of a given method. It is neces-
sary to take into consideration predicted adverse effects, the 
performance status of the patient and her preferences as 
well as the comorbidities. Now it is the beginning of an era 
of genetic tests which are meant to support us in increas-
ing best selection of adjuvant therapy for specific patients. 
There are no definitively perfect solutions. Many patients 
are treated in a suboptimal way and many unnecessarily, as 
only 15% of patients with pN0 status have recurrence of the 
disease, whilst 50% of such patients undergo chemotherapy.
The objective of the study 
The objective of the work was to evaluate the treatment 
algorithm in the application of adjuvant chemotherapy in 
everyday clinical practice in 4 selected oncology centres 
in diverse regions of Poland — Opole, Kraków, Białystok 
and Poznań.
Materials and methods 
A retrospective analysis of adjuvant chemotherapy ap-
plied in a group of 218 patients with early breast cancer 
was performed on the basis of medical documentation. 
These were the patients treated in each of the centres within 
3 consecutive months in 2014.
Table I. The comparison of various chemotherapy regimens in the 
adjuvant treatment of breast cancer 
ER+ and ER– study group RR 2p
CMF vs without CHT 0.76 < 0.0001
CAF vs without CHT 0.64 < 0.0001
4AC/EC vs without CHT 0.78 0.01
4AC vs CMF 0.98 0.67
CAF/CEF vs 4AC 0.78 0.0004
AntraÆTax vs Antra ≤ 240 0.86 0.0005
AntraÆTax vs Antra > 240 0.94 0.33
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All the patients underwent primary surgical treatment fol-
lowed by chemotherapy, and the patients with neoadjuvant 
treatment, patients with infiltrating cancer and patients in 
whose cases adjuvant chemotherapy was abandoned were 
excluded from the analysis. The groups were quite diversified 
with regards to the specific centres. The age median in the en-
tire group of patients was 56, yet there were quite significant 
differences between the centres (Tab. II). In all the analysed 
patients, the complete results of histopathological examina-
tions and immunohistochemistry (IHC) tests, determining 
the expression of the oestrogen receptor (ER), progesterone 
(PgR) and HER2 expression were available. The dominating 
group of cancers were ductal, both moderately and poorly 
differentiated, in more than 50% of cases the cancers showed 
the expression of steroid receptors, whilst in about 5% of cases 
within the group, the steroid receptor status was not known. 
Table II. Pathological and clinical characteristics 
Property Total  
n = 218
Centre 1  
n = 51
Centre 2  
n = 19
Centre 3  
n = 48
Centre 4  
n = 100
Age (years)
median 56 51 45 60 57
scope (30–83) (30–74) (31–62) (32–83) (30–75)
Menopause
before 117 30 11 14 62
after 71 21 8 34 8
no data 30 0 0 0 30
Histological type
ductal 200 43 17 45 95
lobular 8 4 1 2 1
others 10 4 1 1 4
Histological grade 
G1 5 0 0 0 5
G2 88 19 3 25 41
G3 119 28 16 21 54
no data 6 4 0 2 0
Metastases to axillary lymph nodes
0 107 23 10 29 45
1–3 54 16 3 12 23
4 and more 57 12 6 7 32
Ki67
no data 31 0 1 30 0
< 21% 37 5 7 10 15
> 21% 150 46 11 8 85
Oestrogen receptors 
positive 150 29 12 38 71
negative 59 21 3 10 25
no data 9 1 4 0 4
Progesterone receptors
positive 128 24 10 35 59
negative 78 25 3 13 37
no data 12 2 6 0 4
HER2 receptor
0 59 16 7 21 15
1+ 64 4 6 14 40
2+ (FISH performed) 33 (30) 11 (11) 3 (2) 3 (3) 16 (14)
3+ 62 20 3 10 29
No data 0 0 0 0 0
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The HER2 receptor was determined in every case, and in the 
patients with inconclusive results of the IHC test (HER2 2+), 
in 90% of cases, the amplification was tested with the FISH 
method. HER2 positive breast cancer was diagnosed in 75/218 
patients, which makes up 28% of the study group, whilst in 
62 patients the gene amplification was found with the ICH 
test method and in 13 cases — with the FISH test. 
In half of the patients (50.9%; 111/218), metastases to 
axillary lymph nodes were found (pN+ status). Proliferation 
marker Ki-67 was not determined in 30% of patients.
Results 
In the study group, 8 different chemotherapy regimens 
were used (Tab. III). Almost in all the patients (98%), anthra-
cyclines were administered. Most frequently this treatment 
consisted solely in 4 chemotherapy cycles with anthracy-
clines — 4 AC (up to the doxorubicin dose of 240mg/m2) 
or 4 × EC. Such treatment was administered in 41% of cases 
(90/218). Only 2 patients were given CMF regiment and 
1 patient — TC, or rather TCH regiment and this patient was 
treated within a clinical trial.
Taxoids were administered to almost half of the patients 
(48.6%; 106/218), yet in one centre this rate was significantly 
lower. There were two regimens used with almost an equal 
frequency — 4 cycles of docetaxel every 3 weeks and 12 
weekly cycles of paclitaxel. Yet the application of taxoids 
was not completely compliant with the pN+ status, although 
this was the situation in the majority of cases. In some cases, 
these drugs were administered in patients with pN0 status, 
and in some cases, in spite of the presence of metastases 
in the axillary lymph nodes, taxoids were not administered 
(Fig. 1, numeric graph). 27% (30/111) of patients with a pN+ 
status did not receive taxoids in adjuvant treatment. 
No treatment with paclitaxel, in doses every 3 weeks, 
was used in adjuvant therapy and also no application of 
platinum-based chemotherapy was observed. 
HER2 positive breast cancer was diagnosed in 75/218 
patients, making up 28% of the study group; in the same 
group, 14 patients did not receive trastuzumab: in 2 cases 
due to cardiological contraindications and in 12 cases — by 
the size of the primary tumour below 1 cm, which is the 
inclusion criterion in the drug prescription programme. 
In the majority of cases, trastuzumab was administered 
sequentially after the completion of chemotherapy, whilst 
concurrent administration with taxoids was very rare (in two 
centres this method was not used at all).
Discussion 
The introduction of systemic adjuvant treatment has 
changed the face of the natural history of breast cancer, first 
of all by means of a significant decrease in the frequency 
of the occurrence of distant metastases. As a result, the 
chances of curing patients with early breast cancer have 
increased [8]. The analyses performed by EBCTCG clearly 
Table III. Adjuvant treatment 
Property Total  
n = 218
Centre 1  
n = 51
Centre 2 
n = 19
Centre 3  
n = 48
Centre 4  
n = 100
Chemotherapy 
1 — FAC/FEC 19 17 2 0 0
2 — 6xCMF 2 0 0 1 1
3 — TAC 12 11 0 1 0
4 — 4 × AC/EC 90 9 6 32 43
5 — 6 × AC 1 0 0 0 1
6 — antraÆpct q1 51 3 2 0 46
7 — antraÆdct q3 42 10 9 14 9
8 — other (what?) 1 1-TCH 0 0 0
Trastuzumab
without 156 25 17 40 74
after CHT 36 16 2 8 10
with taxoids 21 5 0 0 16
clinical study 5 5 0 0 0
Clincial studies 5/218 5/51 0/19 0/48 0/100
T in HER2+ (IHC/FISH) 75 (62/13) 28 (20/8) 3 (3/0) 12 (10/2) 32 (29/3)
without 14 2 2 4 6
after CHT 41 22 1 8 10
concurrently with taxoids 19 3 0 0 16
clinical study 1 1 0 0 0
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showed that chemotherapy prolongs the time of survival, 
in particular in the patients below 50 years of age [7, 9]. 
Within the 40-year history of this method of treatment a few 
significant landmarks have been observed (the introduc-
tion of polychemotherapy, CMF regimen, anthracyclines, 
taxoids, Trastuzumab), but still the basic challenge of the 
individualisation of treatment, remains i.e. the selection of 
the appropriate treatment methods for specific patients. 
None of the centres participating in the study is dedi-
cated to a specific age group, but some centres treat the 
patients who are younger than the average population. 
Perhaps in some regions of Poland, the migration of young 
people leads to the fact that we treat an older population. 
This analysis does not explain such differences, as it covers 
solely a period of 3 months, and the groups of patients might 
differ with regards to their number. 
In more than half of the patients treated with adjuvant 
chemotherapy, the expression of steroid receptors in the 
tumour was found. The patients with positive oestrogen 
receptors constitute a very heterogenous group with varied 
levels of the HER2 receptor expression or differentiated Ki67 
levels. As is shown by earlier quoted analyses, significant 
benefit of the use of adjuvant chemotherapy is seen in this 
group [7]. In about 5% of patients in the entire group, no 
data on the steroid receptors status were available, which 
is quite disturbing as it is necessary for the decision on 
whether or not to introduce adjuvant therapy. In all the 
patients the HER2 receptor status was determined, and, 
in the case of inconclusive results of the IHC test (Her2 
2+), the FISH test was performed in almost all of the cases 
(90%). The Ki67 status is currently regarded as a necessary 
diagnostic element. In spite of many doubts concerning the 
threshold value of this indicator, it is still very important for 
the determination of the immunochemistry subtype [10]. 
It may provide additional grounds for the application of 
chemotherapy in such patients in the case of moderately dif-
 Figure 2. The rate of patients treated with adjuvant anthracyclines
Figure 1. The use of taxoids, depending on the number of metastases in axillary lymph nodes
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ferentiated cancer with the expression of steroid receptors,. 
In the studied group, the Ki67 status was not determined 
only in the case of patients with poorly differentiated cancer, 
G3, so thus it did not have any influence on the selection of 
the adjuvant systemic therapy.
The majority of the regimens proposed in the recom-
mendations for adjuvant chemotherapy are based on an-
thracyclines, yet the deviation from the application of an-
thracyclines is a valuable method, which may be taken into 
consideration in a group of patients with an increased risk 
of cardiotoxicity, so those in whose case there is a comor-
bidity of not only a reduced left ventricle ejection fraction 
(LVEF), but also hearth ischaemic disease, a long history of 
arterial hypertension or poorly controlled one, obesity, lipid 
metabolism disorders, DM or tobacco smoking. The study 
comparing 4 AC chemotherapy cycles and 4 cycles of doc-
etaxel with cyclophosphamide (TC) showed that treatment 
with the TC regimen was connected with an improvement 
in the progression free survival and overall survival rate and 
the benefit continued throughout a many-year follow-up 
period [11]. The TC regimen was characterised with a differ-
ent adverse reaction profile. In the population of the patients 
with HER2 positive breast cancer, the value of the treatment 
with exclusion of anthracyclines was confirmed, also over 
a many-year-long follow-up period [12]. Such treatment is 
safer for the circulatory system.
In the study group, anthracyclines were administered in 
more than 95% of patients. In other countries, though, the 
application of the drugs from this group is becoming less 
and less common in the adjuvant treatment of the breast 
cancer (Fig. 2) [14]. 
In the presented group, in the majority of patients in 
whose case the regimen with anthracyclines and taxanes 
was applied the AC Æ T sequential therapy was the method 
of treatment. The TAC regimen was applied only in 5.5% 
of patients from the entire group. In one of the centres, 
however, this method of treatment was applied in 20% of 
patients. This may be indicative of the fact that the choice 
of the treatment regimen is also influenced by some other, 
non-medical factors. Treatment according to the TAC regi-
men is shorter and requires fewer visits to the oncology 
centre. The efficiency of both methods is comparable, with 
the application of G-CSF (granulocyte colony-stimulating 
factor) within the TAC therapy; whereas the toxicity is also 
comparable [14].
What is important the treatment according to the regi-
men providing for 6 courses of AC was administered only to 
2 patients, so this was less than 1% of the entire group. Until 
recently in many centres in Poland, such treatment had 
been commonly used. The cardiotoxicity risk connected 
with the application of the standard doxorubicin doses 
(up to 240 mg/m2, and thus 2 courses of treatment in the 
AC regimen) is 2–3%. The application of a higher dose of 
conventional doxorubicin increases the risk of iatrogenic 
heart failure [15]. 
The very rare use of the treatment according to the CMF 
regimen raises some concern. This “classical regimen” of ad-
juvant treatment, introduced 40 years ago, was replaced in 
the 1980s by newer drug combinations containing anthracy-
clines and taxanes [4]. It seems however, that in some clinical 
situations, for example in patients with contraindications for 
the use of anthracyclines and with a low risk of recurrence 
(N0), treatment with the CMF regimen can still be used. 
There are also reports pointing to a higher efficacy of this 
regimen in the group of patients with tumours without the 
steroid receptors expression and without the overexpression 
of the HER2 receptor. In the presented group, the majority 
of patients were younger women in pre-menopausal age. 
In this group, however, there were also women above 70 
or 80 years of age, and the CMF regimen was applied only 
in 2 cases. This is probably the result of a conviction about 
the superiority of 4 AC cycles over 6 CMF courses, whilst the 
efficiency of these 2 courses is comparable [16].Observation 
over many years confirms the safety and persisting efficacy 
of the treatment according to the CMF regimen [17].
In the study group no dose dense chemotherapy was 
used. Such a method of drug dosage has been the subject 
of studies for several years, and the results suggest that 
this may bring additional benefit in particular to groups of 
younger patients not burdened with comorbidities [18–22]. 
The current international recommendations (NCCN, St. Gal-
len, ESMO) allow for dose dense chemotherapy in particular 
in the population of patients with a high risk of recurrence 
(high Ki67 proliferation rate, triple negative breast cancer 
or B luminal cancer) [10, 23, 24]. 
In the study group, the sequential administration of 
Trastuzumab, after the completion of chemotherapy was 
dominant. A number of studies suggest more benefits in 
the concurrent use of Trastuzumab with taxoids. The sur-
vey carried out among oncologists confirms that currently 
this is the most common practice in Europe [25]. 97% of 
participants of the consensus panel at the St. Gallen confer-
ence were in favour of such therapeutic management [10]. 
Current regulations in Poland related to the reporting and 
settlement of the drug programme, however, reduce the 
possibilities of this way of treatment. 
Conclusions 
The development of adjuvant therapy significantly af-
fects the decrease of breast cancer mortality. No standard 
in adjuvant therapy is perfect, however, and breast cancer is 
a diversified disease, so larger individualisation of adjuvant 
therapy is possible.
The collected material points to the common use of an-
thracyclines in the adjuvant treatment. Some of the patients 
with metastases to axillary lymph nodes were not receiving 
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taxoids. Trastuzumab was most frequently administered 
sequentially, which is not an optimum management. The 
studied group was not representative, yet it reflected the 
everyday practice throughout many regions of Poland.
This is a pilot study. The authors are considering the 
invitation of other investigators from other Polish centres 
and plan to broaden the analysis with regards to the im-
munohistochemistry subtypes and the choice of adjuvant 
chemotherapy.
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